What question did this study set out to answer?

To synthesize historical developments, biological mechanisms, and therapeutic strategies regarding cancer therapy–induced cardiovascular complications.

August 19, 2016JAMA Cardiology

Oncocardiology—Past, Present, and Future

Q: What is the clinical evidence from this study?

Study design: Review. Population: Cancer therapy-induced cardiovascular complications. Intervention: Cancer therapy.

View Full Paper

Ask AI

Bookmark

Key result

Oncocardiology focuses on identifying, preventing, and treating cardiovascular complications of cancer therapies, requiring close collaboration between cardiologists and oncologists.

Population

Cancer survivors and patients receiving cancer therapies

Design

Review

Authors

EYEdward T.H. YehCross-Cutting Cardiology HCHui‐Ming ChangTufts University

Discussion

Member takes

Implication

Emphasizes multidisciplinary cardio-oncology integration in cancer care; leaves open standardized protocols for routine implementation.

Key Points

To synthesize historical developments, biological mechanisms, and therapeutic strategies regarding cancer therapy–induced cardiovascular complications.
Reviewed mechanistic pathways underlying cardiotoxicity induced by conventional anthracyclines and targeted anticancer therapeutics.
Evaluated diagnostic screening tools, including strain echocardiography and biomarkers, alongside early cardioprotective interventions.
Anthracycline cardiotoxicity is mediated by topoisomerase II β targeting, causing DNA double-strand breaks, transcriptomic alterations, reactive oxygen species generation, and mitochondriopathy.
Targeted agents induce cardiac dysfunction via on-target HER2 disruption or off-target impairment of vascular endothelial growth factor signaling and stress-induced angiogenesis.
Early detection using global strain imaging and cardiac biomarkers facilitates prompt initiation of heart failure pharmacotherapies to prevent late-stage cardiotoxic complications.

Structured PICO

Population

Cancer survivors and patients receiving cancer therapies

Exposure

Cancer therapies (anthracyclines, trastuzumab, tyrosine kinase inhibitors) and heart failure medications for prevention of cardiotoxicity

Close collaboration between cardiologists and oncologists, along with early detection and treatment, is essential to manage cancer therapy-induced cardiovascular complications.

Cite This Study

Yeh et al. (2016) conducted a review in Cancer therapy-induced cardiovascular complications. Cancer therapy was evaluated. Oncocardiology focuses on identifying, preventing, and treating cardiovascular complications of cancer therapies, requiring close collaboration between cardiologists and oncologists.

synapsesocial.com/papers/6a79f9524c448619ca0df550 https://doi.org/10.1001/jamacardio.2016.2132

View Full Paper

Ask AI

Bookmark

Oncocardiology—Past, Present, and Future

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Oncocardiology—Past, Present, and Future

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider